Romanos Sklavenitis-Pistofidis, Instructor at Dana-Farber Cancer Institute, shared a post on X about a paper he coauthored with colleagues published in Blood Journal:

“Our paper on establishing targeted therapy for MM with 1q+ is online ahead of print in Blood Journal with Liz Lightbody, Mairead Reidy, Irene Ghobrial, Gaddy Getz and Salomon Manier!

We used a variety of approaches, including dependency screens, drug screens, scRNA-seq of patient tumors with subclonal 1q+, and single-cell cloning of a MM cell line! Tweetorial to follow upon publication!”

“Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q+”

Authors: Romanos Sklavenitis-Pistofidis, Elizabeth Lightbody, Mairead Reidy, Junko Tsuji, Jean-Baptiste Alberge, Michelle Aranha, Matthew Davids, Maria Papaioannou, Gad Getz, Irene Ghobrial, Salomon Manier et al.

Romanos Sklavenitis-Pistofidis: Establishing targeted therapy for Multiple Myeloma with 1q+

More posts featuring Romanos Sklavenitis-Pistofidis.